REVB REVELATION BIOSCIENCES, INC.

CIK 0001810560 50 ready 8-Ks latest June 24, 2026, 4:47 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing June 24, 2026, 4:47 PM ET

Top materiality 0.85

Event mix other_material ×24 · earnings ×12 · regulatory ×7

Sentiment 12 pos · 10 neg · 28 neu

Latest earnings reported 2026-Q1

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for REVB

Highest-materiality recent filing

Revelation Biosciences reaches FDA agreement on approval pathway for Gemini AKI treatment

January 22, 2026, 6:59 PM ET regulatory materiality 0.85 positive item 8.01 item 9.01

FDA agreed single Phase 2/3 adaptive study (~300 patients) can support NDA for Gemini in AKI.
Primary composite endpoint: death and/or need for dialysis; clinically relevant and objective.

Read filing →

June 24, 2026, 4:47 PM ET other material materiality 0.65 neutral item 5.02 item 5.03 item 5.07 item 9.01

Revelation Biosciences adopts bylaw amendments, authorizes reverse stock split

Board approved amended employment agreements for CEO & CFO: 2x salary+bonus severance on change in control, 18-mo COBRA, 3-year term.
February 26, 2026, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Revelation Biosciences reports Q4 and FY2025 results; cash $10.7M, net loss $8.9M

Cash and cash equivalents $10.7M as of Dec 31, 2025 vs $6.5M in 2024; net proceeds of $6.7M from warrant inducement in January 2026
January 29, 2026, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 3.02 item 3.03 item 9.01 ◈ Equity Issuances◈ Material Agreements

Revelation Biosciences raises ~$7.3M via warrant exercise; issues new warrants

Two holders exercised 8,544,999 pre-split Class I warrants at $0.86/share, gross proceeds ~$7.3M.
January 22, 2026, 6:59 PM ET regulatory materiality 0.85 positive item 8.01 item 9.01

Revelation Biosciences reaches FDA agreement on approval pathway for Gemini AKI treatment

FDA agreed single Phase 2/3 adaptive study (~300 patients) can support NDA for Gemini in AKI.
December 3, 2025, 6:59 PM ET other material materiality 0.75 positive item 3.03 item 5.07 item 8.01 item 9.01

Revelation Biosciences reports positive Phase 1b Gemini results; plans Phase 2/3 AKI study in 2026

Phase 1b CKD study completed with positive results; Gemini rebalances inflammation at cellular level.
November 6, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Revelation Biosciences Q3 net loss $1.9M, cash $12.7M; cash runway through Q3 2026

Net loss for Q3 2025 was $1.9M ($1.77 per share) vs $2.2M ($40.15) in Q3 2024.
September 15, 2025, 7:59 PM ET other material materiality 0.75 positive item 1.01 item 3.02 item 3.03 item 8.01 item 9.01 ◈ Equity Issuances

Revelation Biosciences raises $9.6M via immediate exercise of existing warrants

$9.6M gross proceeds from exercise of 13,065,000 existing warrants at $2.20/share.
September 9, 2025, 7:59 PM ET other material materiality 0.85 positive item 8.01 item 9.01

Revelation Biosciences PRIME Phase 1b CKD study hits endpoints; Gemini reduces inflammation in high-background patients

Gemini met primary safety endpoint; well-tolerated at target dose with only mild Grade I events.
June 25, 2025, 7:59 PM ET other material materiality 0.65 negative item 5.07 item 8.01 item 9.01

Revelation Bio shareholders approve reverse split up to 1:250; Nevada reincorporation fails despite 89% support

Reverse stock split authorized at ratio 1:2 to 1:250, board to set exact ratio within one year.
June 4, 2025, 7:59 PM ET other material materiality 0.65 neutral item 1.01 item 3.03 item 8.01 item 9.01

Revelation Biosciences closes $4M public offering of common stock and warrants

Gross proceeds ~$4M from sale of 3,640,000 shares (or pre-funded warrants) plus warrants for up to 14,560,000 shares.
May 8, 2025, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01

Revelation Biosciences Q1 net loss $2.1M; cash only to June 2025

Cash and equivalents $3.7M at March 31, 2025, down from $6.5M at Dec 31, 2024.
March 17, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Gemini priming attenuates inflammation in human PBMCs; Phase 1b data expected mid-2025

Gemini significantly decreased proinflammatory cytokines and increased anti-inflammatory cytokines vs. placebo in PBMCs challenged with HMGB-1 and LPS.
March 6, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Revelation Biosciences reports FY2024 net loss of $15.0M; cash at $6.5M, expects to fund ops into 2025

Q4 2024 net loss $1.7M ($4.98/share) vs $2.2M ($133.64/share) in Q4 2023.
February 24, 2025, 6:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

Revelation Biosciences regains Nasdaq compliance and advances PRIME Phase 1b CKD study

Nasdaq confirmed REVB common stock meets minimum bid price and all continued listing requirements.
January 30, 2025, 6:59 PM ET other material materiality 0.60 neutral item 3.03 item 5.03 item 9.01 ◈ Governance Changes

Revelation Biosciences effects 1-for-16 reverse stock split; shares outstanding cut to ~522K

Reverse stock split effective Jan 28, 2025, at 1-for-16 ratio; no fractional shares issued.
January 7, 2025, 6:59 PM ET regulatory materiality 0.75 neutral item 3.01 item 8.01 item 9.01 ◈ Listing & Compliance Notices ×2

Nasdaq grants Revelation continued listing subject to reverse split and $1 price by Feb 14, 2025

Nasdaq Panel granted continued listing; must effect reverse stock split by Jan 31, 2025.
December 12, 2024, 6:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Revelation Biosciences regains compliance with Nasdaq stockholders' equity requirement

Reported stockholders' equity of $2.67M as of Sep 30, 2024, meeting the $2.5M minimum.
December 6, 2024, 6:59 PM ET regulatory materiality 0.75 positive item 1.01 item 3.02 item 3.03 item 8.01 item 9.01

FDA accepts IND for Gemini Phase 1b CKD study; REVB raises ~$4.1M from warrant exercises

FDA accepted IND for Gemini (trained immunity) for Phase 1b study in up to 40 CKD patients; primary endpoint safety/tolerability.
November 8, 2024, 6:59 PM ET earnings materiality 0.65 negative item 2.02 item 9.01

Revelation Biosciences reports Q3 net loss of $2.2M; cash $6.5M into 2025

Net loss Q3 2024: $2.2M ($0.84 per share) vs $2.6M loss in Q3 2023; nine-month net loss $13.3M vs net income $2.1M in prior year.
October 21, 2024, 7:59 PM ET regulatory materiality 0.80 negative item 3.01 item 9.01

Revelation Biosciences receives Nasdaq deficiency notices for bid price and stockholders' equity; intends to appeal

Nasdaq notified REVB of non-compliance with $1.00 minimum bid price rule as of October 16, 2024.
September 27, 2024, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Revelation Biosciences reports Gemini induces dose-dependent IL-10 increases up to 309-fold in Phase 1

Gemini induced statistically significant (p<0.05) dose-dependent IL-10 increases: 27-fold (low), 162-fold (mid), 309-fold (high) vs placebo at 2 hours.
August 26, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.02 item 3.03 item 8.01 item 9.01

Revelation Biosciences raises ~$3.8M via warrant exercises; issues new warrants

Class D warrant holders exercise 2,548,060 shares at reduced price of $1.50/share, gross proceeds ~$3.8M.
August 19, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 3.01 item 9.01

Revelation Biosciences warns of delisting risk; stockholders' equity only $1.14M vs $2.5M minimum

Received Nasdaq letter on Aug 14, 2024, citing insufficient stockholders' equity of $1,140,421 vs required $2.5M.
August 9, 2024, 7:59 PM ET earnings materiality 0.60 negative item 2.02 item 9.01

Revelation Biosciences Q2 net loss $8.4M; cash $12.1M, plans Phase 1b

Net loss for Q2 2024 of $8.4M ($5.13 per share) vs $1.4M loss in Q2 2023.
August 2, 2024, 7:59 PM ET litigation materiality 0.60 negative item 8.01 item 9.01

Revelation Biosciences faces $7.3M judgment in LifeSci Capital lawsuit

U.S. District Court entered summary judgment against Revelation Biosciences for ~$7.3M in unpaid banking and advisory fees plus interest.
May 10, 2024, 7:59 PM ET earnings materiality 0.60 negative item 2.02 item 9.01 ◈ Earnings Releases

Revelation Biosciences Q1 net loss $2.7M; cash $14.6M sufficient through 2024

Net loss of $2.7M ($2.46 per share) for Q1 2024, compared to net earnings of $6.2M in Q1 2023, driven by change in warrant liability.
March 22, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases ×2

Revelation Biosciences FY2023 net loss narrows to $0.1M; cash $12.0M through 2024

Year-end cash $12.0M vs $5.3M; company believes sufficient to fund operations through 2024.
March 12, 2024, 7:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Revelation presents positive preclinical Gemini data for AKI; Phase 1 initiated

Gemini (PHAD) significantly reduced serum BUN, creatinine, and urine CRP in rat AKI model at 0.35 mg/kg (p<0.05).
February 8, 2024, 6:59 PM ET other material materiality 0.65 positive item 1.01 item 3.03 item 8.01 item 9.01 ◈ Material Agreements ×2

Revelation Biosciences raises $6.2M in public offering, regains Nasdaq bid price compliance

Gross proceeds ~$6.2M from sale of 128,470 shares and 1,236,530 pre-funded warrants, plus 2,730,000 Class D warrants at $4.53 combined price.
October 12, 2023, 7:59 PM ET other material materiality 0.65 positive item 7.01 item 8.01 item 9.01

Revelation Biosciences reports preclinical Gemini data showing biomarker activity; Phase 1 study planned

Gemini showed dose-dependent white blood cell mobilization and cytokine upregulation (IL-10, NGAL, IL-6) in healthy animal models.
August 11, 2023, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

Revelation Biosciences receives Nasdaq bid price deficiency notice

Nasdaq notified REVB on Aug 8, 2023 of noncompliance with minimum $1.00 bid price rule for 30 consecutive business days.